SCHEMBL26925285

SCHEMBL26925285

O=C1CCC(c2cccc(C(=O)O)c2)C(=O)N1

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 18/20 0.65
▸ CRBN Q96SW2 18/20 0.65
▸ KMO O15229 1/20 0.50
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30706220 1.00 DDB1 (0.65) DDB1CRBNKMOPOLB
SCHEMBL31678136 0.87 DDB1 (0.66) DDB1CRBNPOLB
SCHEMBL27119032 0.82 CRBN (0.68) DDB1CRBNPOLB
SCHEMBL30993782 0.81 CRBN (0.68) DDB1CRBNPOLB
SCHEMBL31678103 0.80 DDB1 (0.53) DDB1CRBN
SCHEMBL31704110 0.80 CRBN (1.00) DDB1CRBNPOLB
SCHEMBL31704153 0.80 CRBN (1.00) DDB1CRBNPOLB
SCHEMBL2107934 0.80 CRBN (1.00) DDB1CRBNPOLB
SCHEMBL30643591 0.80 CRBN (0.60) DDB1CRBN
SCHEMBL31161726 0.78 DDB1 (0.50) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-08-28 — — US disclosed
EP-4536649-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
WO-2023244918-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-21 — — WO disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR DDB1 92/4885CRBN 885/4885KMO 2040/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR DDB1 92/4885CRBN 885/4885KMO 2040/4885
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR DDB1 141/4885CRBN 756/4885KMO 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback